Home » Stocks » MACK

Merrimack Pharmaceuticals, Inc. (MACK)

Stock Price: $3.78 USD -0.01 (-0.26%)
Updated November 25, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 50.58M
Revenue (ttm) n/a
Net Income (ttm) 1.34M
Shares Out 13.38M
EPS (ttm) 0.10
PE Ratio 37.80
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $3.78
Previous Close $3.79
Change ($) -0.01
Change (%) -0.26%
Day's Open 3.79
Day's Range 3.74 - 3.80
Day's Volume 22,028
52-Week Range 1.49 - 4.75

More Stats

Market Cap 50.58M
Enterprise Value 34.76M
Earnings Date (est) May 13, 2021
Ex-Dividend Date n/a
Shares Outstanding 13.38M
Float 13.14M
EPS (basic) 0.09
EPS (diluted) 0.10
FCF / Share -0.41
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.65%
FCF Yield n/a
Payout Ratio 555.60%
Shares Short 497,943
Short Ratio 32.17
Short % of Float 3.79%
Beta 2.54
PE Ratio 37.80
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.97
Revenue n/a
Operating Income -4.20M
Net Income 1.34M
Free Cash Flow -5.49M
Net Cash 15.81M
Net Cash / Share 1.18
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.08%
ROE -14.08%
ROIC -15.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.00*
Low
4.00
Current: $3.78
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-----10347.7948.9234.2220.31
Revenue Growth-----115.03%-2.32%42.98%68.51%-
Gross Profit-----10347.7948.9234.2220.31
Operating Income-22.36-65.58-95.77-147-145-66.26-121-92.74-80.87-49.18
Net Income-17.33-40.51472-152-148-83.29-131-91.28-79.22-50.10
Shares Outstanding13.3513.3413.2312.5311.1410.449.897.281.131.10
Earnings Per Share-1.30-3.0335.67-12.11-13.29-8.00-13.20-12.80-76.70-55.70
Dividend Per Share2.00-10.55-------
Operating Cash Flow-31.37-65.59-126-170-105-34.81-95.18-79.82-52.82-26.37
Capital Expenditures2.03-0.040.18-2.64-11.90-6.04-9.86-3.19-3.75-5.00
Free Cash Flow-29.34-65.63-126-173-117-40.84-105-83.01-56.57-31.37
Cash & Equivalents16.5871.8694.2222.3018612515611150.8431.09
Total Debt-14.87-21725812011239.860.050.49
Net Cash / Debt16.5856.9994.22-195-71.364.7144.2170.7350.7930.60
Assets20.0888.5411781.4823515919214985.3057.58
Liabilities2.7729.7221.0433441926123615510785.26
Book Value17.3158.8296.28-250-184-102-43.80-6.61-291-221
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Merrimack Pharmaceuticals, Inc.
Country United States
CEO Gary L. Crocker

Stock Information

Ticker Symbol MACK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MACK
IPO Date March 29, 2012

Description

Merrimack Pharmaceuticals is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.